Table 4 Quality of life and treatment satisfaction at baseline and 9 months
Hizentra N = 117 | |
|---|---|
SF-36 physical component summary | |
Baseline, N | 99 |
Mean ± SD | 46.4 ± 10.0 |
Median [range] | 48.4 [23.5;63.1] |
Follow-up, N | 95 |
Mean ± SD | 46.3 ± 10.0 |
Median [range] | 48.0 [23.6;62.6] |
Change from baseline, N | 92 |
Mean ± SD | −0.3 ± 8.9 |
SF-36 mental component summary | |
Baseline, N | 99 |
Mean ± SD | 45.6 ± 10.1 |
Median [range] | 46.9 [16.2;62.0] |
Follow-up, N | 95 |
Mean ± SD | 46.6 ± 9.3 |
Median [range] | 48.2 [18.8;62.8] |
Change from baseline, N | 92 |
Mean ± SD | 1.1 ± 10.2 |
TSQM, N | 94–96a |
Effectiveness, mean ± SD | 75.4 ± 14.9 |
Side effects, mean ± SD | 88.3 ± 21.2 |
Convenience, mean ± SD | 69.9 ± 19.9 |
Global satisfaction, mean ± SD | 74.2 ± 19.3 |